GlassScriptPhysician profile
Annette C Fontaine
NPI 1346234788
$207,854.40
in general payments reported to CMS, 2019-2025
51 companies · $26K in 2025
The $26K reported for 2025 was more than what 91% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15K · 2020: $42K · 2021: $25K · 2022: $38K · 2023: $37K · 2024: $24K · 2025: $26K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $64K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $17K · Travel and Lodging: $3,207 · Food and Beverage: $2,666 · Honoraria: $500 · Education: $109.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $63,749.05 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $17,360.00 |
| Travel and Lodging | $3,206.98 |
| Food and Beverage | $2,666.11 |
| Honoraria | $500.00 |
| Education | $109.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $87,773.53 | 2019-2025 | Enhertu, Datroway |
| Astrazeneca Pharmaceuticals LP | $31,110.71 | 2021-2024 | Calquence, Lynparza |
| Stemline Therapeutics INC. | $18,845.95 | 2023-2025 | Orserdu |
| E.R. Squibb & Sons, L.L.C. | $12,158.80 | 2019-2025 | Opdivo, Opdualag |
| Incyte Corporation | $10,018.90 | 2019-2025 | Monjuvi |
| Astellas Pharma US INC | $7,573.03 | 2021-2024 | Xtandi |
| Jazz Pharmaceuticals INC. | $5,884.58 | 2019-2021 | |
| Pfizer INC. | $5,594.79 | 2020-2024 | |
| Aurobindo Pharma USA, INC. | $3,660.88 | 2019 | |
| Janssen Biotech, INC. | $2,708.84 | 2019-2025 | Tecvayli, Darzalex, Rybrevant |
| Emd Serono, INC. | $2,074.55 | 2020-2022 | |
| Glaxosmithkline, LLC. | $1,857.46 | 2020 | |
| Beigene USA, INC. | $1,835.98 | 2020-2024 | Brukinsa |
| Heron Therapeutics, INC. | $1,699.46 | 2019 | |
| Karyopharm Therapeutics INC. | $1,619.80 | 2020-2021 |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Annette Fontaine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.